Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Kidney Cancer | Research

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma

Authors: Yin Huaqi, Dong Bingqi, Zhao Yanhui, Ma Yongkang, Zhao Shiming, Sun Zhenghui, Du Zheng, Peng Jiangshan, Yang Tiejun

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

In recent years, hyperthermia has been widely applied as a novel strategy for cancer treatment due to its multiple antitumour effects. In particular, the potential influences of hyperthermia on the tumour immune microenvironment may improve the efficacy of immunotherapies. However, the effect of hyperthermia on renal cell carcinoma (RCC) has not been well characterized until now.

Methods

In the present study, we primarily evaluated the effects of hyperthermia on cellular function via cellular proliferation, migration, invasion and apoptosis assays. In addition, the influence of hyperthermia on the immunogenicity of RCC cells was analysed using flow cytometry analysis, enzyme-linked immunosorbent assays, and immunofluorescent (IF) staining.

Results

Our results demonstrate that hyperthermia significantly inhibits RCC cell proliferation, migration, and invasion and promotes cell apoptosis. In addition, we verified that hyperthermia improves the immunogenicity of RCC cells by inducing immunogenic cell death.

Conclusion

Our findings suggest that hyperthermia is a promising therapeutic strategy for RCC.
Literature
1.
Golovastova MO, Korolev DO, Tsoy LV, Varshavsky VA, Xu WH, Vinarov AZ, Zernii EY, Philippov PP, Zamyatnin AJ. Biomarkers of renal tumors: the current state and clinical perspectives. CURR UROL REP. 2017;18(1):3.CrossRefPubMed
2.
Huaqi Y, Caipeng Q, Qiang W, Yiqing D, Xiang D, Xu T, Xiaowei Z, Qing L, Shijun L, Tao X. Transcription factor SOX18 promotes clear cell renal cell carcinoma progression and alleviates cabozantinib-mediated Inhibitory Effects. MOL CANCER THER. 2019;18(12):2433–45.CrossRefPubMed
3.
Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, Zhang W. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers (Basel) 2021, 13(22).
4.
Ballesteros PA, Chamorro J, Roman-Gil MS, Pozas J, Gomez DSV, Granados AR, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021, 13(23).
5.
Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D et al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and Meta-analysis. Cancers (Basel) 2020, 12(2).
6.
Yang DC, Chen CH. Potential new therapeutic approaches for renal cell carcinoma. SEMIN NEPHROL. 2020;40(1):86–97.CrossRefPubMed
7.
Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022;8(1):9–20.CrossRefPubMed
8.
Feng F, Cao X, Liu X, Qin J, Zhang S, Li Q, Liu J. The Effect of Pancreatoduodenectomy Plus Intraperitoneal Hyperthermic Perfusion on Resectable Pancreatic Head Cancer: Cohort Study. ANN SURG ONCOL. 2021;28(4):2337–45.CrossRefPubMed
9.
Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. Survival after Hyperthermic Intraperitoneal Chemotherapy and primary or interval cytoreductive surgery in ovarian Cancer: a Randomized Clinical Trial. JAMA SURG. 2022;157(5):374–83.CrossRefPubMedPubMedCentral
10.
Kolosnjaj-Tabi J, Marangon I, Nicolas-Boluda A, Silva A, Gazeau F. Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix. PHARMACOL RES. 2017;126:123–37.CrossRefPubMed
11.
Ruan Q, Ding D, Wang B, He C, Ren X, Feng Z, Pang Z, Wang J, Zhang X, Tang H, et al. A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer. CANCER BIOL MED. 2021;18(1):308–17.CrossRefPubMedPubMedCentral
12.
Maurici CE, Colenbier R, Wylleman B, Brancato L, van Zwol E, Van den Bossche J, Timmermans JP, Giovannetti E, Mori DCM, Bogers J. Hyperthermia enhances efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. Biomolecules 2022, 12(5).
13.
Mukherjee PK, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum MA, Salata RA. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC INFECT DIS. 2017;17(1):74.CrossRefPubMedPubMedCentral
14.
Wang Z, Guo B, Middha E, Huang Z, Hu Q, Fu Z, Liu B. Microfluidics-Prepared Uniform Conjugated Polymer Nanoparticles for Photo-Triggered Immune Microenvironment Modulation and Cancer Therapy. ACS Appl Mater Interfaces. 2019;11(12):11167–76.CrossRefPubMed
15.
Chen Q, Hu Q, Dukhovlinova E, Chen G, Ahn S, Wang C, Ogunnaike EA, Ligler FS, Dotti G, Gu Z. Photothermal Therapy promotes Tumor Infiltration and Antitumor Activity of CAR T cells. ADV MATER. 2019;31(23):e1900192.CrossRefPubMedPubMedCentral
16.
Yang X, Gao M, Xu R, Tao Y, Luo W, Wang B, Zhong W, He L, He Y. Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors. FRONT IMMUNOL. 2022;13:969447.CrossRefPubMedPubMedCentral
17.
Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56.CrossRefPubMed
18.
Mircheva I. [The mechanisms of the cytotoxic action of hyperthermia]. Eksp Med Morfol. 1991;30(1):51–4.PubMed
19.
Adkins I, Sadilkova L, Hradilova N, Tomala J, Kovar M, Spisek R. Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. ONCOIMMUNOLOGY. 2017;6(5):e1311433.CrossRefPubMedPubMedCentral
20.
Takaki H, Cornelis F, Kako Y, Kobayashi K, Kamikonya N, Yamakado K. Thermal ablation and immunomodulation: from preclinical experiments to clinical trials. Diagn Interv Imaging. 2017;98(9):651–9.CrossRefPubMed
21.
Mouratidis P, Costa M, Rivens I, Repasky EE, Ter Haar G. Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. J R SOC INTERFACE. 2021;18(180):20210266.CrossRefPubMedPubMedCentral
22.
Wang S, Song Y, Cao K, Zhang L, Fang X, Chen F, Feng S, Yan F. Photothermal therapy mediated by gold nanocages composed of anti-PDL1 and galunisertib for improved synergistic immunotherapy in colorectal cancer. ACTA BIOMATER. 2021;134:621–32.CrossRefPubMed
23.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. NAT MED. 2007;13(1):54–61.CrossRefPubMed
24.
25.
Feng M, Jiang W, Kim B, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. NAT REV CANCER. 2019;19(10):568–86.CrossRefPubMedPubMedCentral
26.
Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J IMMUNOL. 2009;182(3):1449–59.CrossRefPubMed
27.
28.
Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garcia T, Salazar L, et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. CLIN CANCER RES. 2011;17(8):2474–83.CrossRefPubMed
Metadata
Title
Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma
Authors
Yin Huaqi
Dong Bingqi
Zhao Yanhui
Ma Yongkang
Zhao Shiming
Sun Zhenghui
Du Zheng
Peng Jiangshan
Yang Tiejun
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11106-8

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Regular gastroscopy and colonoscopy during the evaluation of urachal cancer: do we really need them?

Retraction Note

Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Research

Association of neutrophil–lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy

Research

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Research

Prognostic significance of HLA-G in patients with colorectal cancer: a meta-analysis and bioinformatics analysis

Research

Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits